Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-641988 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A1 | EXPERIMENTAL | Active |
| Name | Type | Description |
|---|---|---|
| BMS-641988 (AR#2) | DRUG | Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks |
Inclusion Criteria: * Patients with castration-resistant prostate cancer and serum testosterone ≤50 ng/dL progressive to current therapy who satisfy the inclusion and exclusion criteria
Top 20 of 53 competitors
BMS-641988 is an investigational small molecule being studied for the treatment of castration resistant prostate cancer. It is being developed by Bristol-Myers Squibb Company. As of the available data, it is in Phase 1 clinical development and has not been approved by regulatory authorities.
BMS-641988 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The drug is an investigational small molecule in Phase 1 clinical development for prostate cancer.
BMS-641988 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. A Phase 1 study of the drug in Japanese patients with castration resistant prostate cancer has been completed.
BMS-641988 has one completed clinical trial, identified as NCT00644488. This was a Phase 1 study in Japanese patients with castration resistant prostate cancer, enrolling 7 male participants aged 20 years and older. The trial was uncontrolled and not randomized or blinded.
BMS-641988 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for prostate cancer. The available data shows one completed Phase 1 trial, but no approval status has been established.